Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Roivant SciencesROIV -0.06%51 Debt-to-Equity is 0.02 as of Mar. 2026, which is 75% below its 10-year median of 0.08. GuruFocus rates ROIV with a GF Score™ of 51/100 and a GF Value™ of $11.22 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 966 Biotechnology companies, Roivant Sciences ranks better than 88.1% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Roivant Sciences's Debt-to-Equity or its related term are showing as below:
ROIV'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.08 Max: 0.42
Current: 0.02
During the past 6 years, the highest Debt-to-Equity Ratio of Roivant Sciences was 0.42. The lowest was 0.01. And the median was 0.08.
ROIV's Debt-to-Equity is ranked better than 88.1% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs ROIV: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Roivant Sciences Debt-to-Equity Related Terms
Roivant Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Roivant Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROIV vs RPRX, BNTX, INCY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Roivant Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences (ROIV) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Roivant Sciences and its competitors. This is 75% below median its historical median of 0.08. Over the past decade, Roivant Sciences' Debt-to-Equity has ranged from 0.01 to 0.42. According to the industry distribution chart, Roivant Sciences ranks #115 out of 966 companies in the Biotechnology industry, placing it in the top 11.9%.
Is Roivant Sciences' Debt-to-Equity too high?
Roivant Sciences' current Debt-to-Equity of 0.02 is 75% below median its 10-year median of 0.08. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.42. The Biotechnology industry median Debt-to-Equity is 0.16. Roivant Sciences' value of 0.02 is 87.5% below this industry median. Based on the distribution chart, Roivant Sciences ranks #115 out of 966 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Roivant Sciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Debt-to-Equity compare to RPRX and BNTX?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #115 out of 966 companies for Debt-to-Equity. This places Roivant Sciences in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Roivant Sciences' value of 0.02 is 87.5% below this benchmark. Historically, Roivant Sciences' own Debt-to-Equity has ranged from 0.01 to 0.42 over the past decade. While the company's 10-year median is 0.08 vs. the industry median of 0.16, Roivant Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roivant Sciences's current Debt-to-Equity of 0.02 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Roivant Sciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roivant Sciences's current Debt-to-Equity is 0.02, which is 75% below median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.22, compared to a current price of $34.89 — trading 211% above its estimated fair value. The current Debt-to-Equity is 0.02, which is 75% below median its 10-year median of 0.08 and 87.5% below the Biotechnology industry median of 0.16. Roivant Sciences' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roivant Sciences (ROIV) Overvalued in 2026?
Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued.
The current stock price of $34.89 is trading 211% above its estimated GF Value™ of $11.22.
GuruFocus considers Roivant Sciences to be Significantly Overvalued.
Key valuation signals for ROIV:
Debt-to-Equity: 0.02 (75% below median its 10-year median of 0.08)
GF Value™: $11.22 vs. price of $34.89 (211% above fair value)
Industry Position: 87.5% below the Biotechnology median (#115 of 966)
No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score
Get the complete analysis for ROIV
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROIV has been successfully added to your 
